go to contents go to 1depth menu
Preparing our future with R&D

R&D introduction

CJ HealthCare is performing ceaseless research activities to bring up the next generation products with its competitive R&D capacity and experience.

HEAL THE WORLD, BETTER LIFE

R&D Goals

  • Disease-
    Focus
    Developing disease-focused & innovative medicines and biologicals
  • Open
    Innovation
    Accelerating R&D process and bringing positive outputs by open innovation
  • Distinguished technologies Blockbuster generic products and IMD products development
  • Platform technologies Exporting technologies/products globally

CJ HealthCare R&D Center is expanding research area based on its platform technology as well as research capabilities along with the initiative to make a new leap toward a global pharmaceutical company by 2020
To achieve the vision “Heal The World, Better Life”, CJ HealthCare R&D Center is performing diversified research activities.

비디오 설명
CJ HealthCare Corp. Osong Plant

R&D achievements

We are leading the way to becoming a global pharmaceutical company in 2020.

  • 2016
    MACHKHAN
    Launched MACHKHAN, fixed dose combination IMD for hypertension
    • ARB/CCB combination drug
    • First Candesartan / Amlodipine combination drug
  • 2016
    Won the 17th Korea New Drug Development Award Technology Export Award
    New drug for Gastroesophageal acid reflux CJ-12420(Tegoprazan)
    • P-CAB (Potassium -Competitive Acid Blocker) New Drug
    • Technology export to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China (2015)
    • New Drug Application (2017)
  • 2014
    VOGMET
    Launched VOGMET, fixed dose combination IMD for Diabetes
    • α-glucosidase/biguanides combination drug
    • First Voglibose/Metformin combination drug
  • 2013
    EXONE
    Launched EXONE, combination drug for hypertension
    • ARB/CCB combination drug
    • Valsartan / Amlodipine combination drug
    • Excellent optical (light) stability with differentiated technology
  • 2012
    Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
    Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
    • Accredited in ‘Excellence in new drug R & D capability and overseas expansion capability’
  • 1998
    EPOKINE
    Launched EPOKINE, renal anemia treatment
    • Developed the first EPO(erythropoietin) in Korea and the third in the world
  • 1995
    CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
    CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
    • Used the first in-vivo substance, TOF, in Korea
  • 1992
    CONDITION
    Launched CONDITION, a nationwide anti hangover drink
    • The first anti-hangover drink in Korea
  • 1986
    HEPACCINE-B
    Launched HEPACCINE-B, Hepatitis B vaccine
    • first-developed in Korea
    • World's 2nd hepatitis B vaccine HEPACCINE-B, obtained WHO certification (1993)

R&D ORGANIZATION

R&D
Business Development Headquaters
R&D
Center
  • Research Planning Team
  • Hybrid Medicine Center
  • New Drug Research Center
  • Biopharmaceutical Center
  • Drug Evaluation Center
  • Drug Analysis Center
Clinical
Development Division
  • Clinical Information Team
  • Registration Team
  • Licensing Team
  • Clinical Team
  • Medical Affairs Team
Business Development Division
  • Business Development Team
  • Global Business Team
R&D
Strategy Team